In germfree mice, the administration of short-chain fatty acids (SCFA) protected the intestinal mucosa from damage produced by 1-␤-D-arabinofuranosylcytosine (Ara-C). Animals receiving SCFA and Ara-C had intestinal morphologies closer to normal than the control animals, which had severe intestinal lesions. We concluded that orally administrated SCFA reduce intestinal lesions, improving the mucosa pattern of the small intestine and colon.
Our group, studying the effects of short-chain fatty acids (SCFA) in mice, demonstrated that orally administered SCFA were able to prevent the intestinal necrosis caused by 1-␤-Darabinofuranosylcytosine (Ara-C) in animals fed on commercial or elemental diets (11) . However, mice have a constant production of SCFA by intestinal flora that could have contributed to the effects of oral administration.
We examined the protection seen in conventionally reared mice to see if it was maintained in germfree mice receiving SCFA orally (ad libitum) or intragastrically (single dose, 15ϫ concentrated). Thirty germfree mice were used. They were kept germfree according to established procedures (10, 13) . Four experimental groups were designed: SCFA/OϩAra-C, SCFA/IGϩAra-C, Placebo/OϩAra-C, and Placebo/IGϩ Ara-C, designating animals receiving oral (O) or intragastric (IG) SCFA and saline solution for 9 days and intraperitoneal Ara-C in the last 2 days.
Three control groups included SCFA/OϩSal and SCFA/ IGϩSal, receiving SCFA and saline solution (Sal) instead of Ara-C, and Normal, which received water and a sterile commercial diet ad libitum for 9 days. All mice were sacrificed 4 h after the last Ara-C or saline dose. Oral SCFA solutions consisted of acetic, pronionic, and butyric acids (35, 15, and 9 mM, respectively). The intragastric solution had the same SCFA proportion in a 15ϫ concentrated solution. The volume of intragastrically administered SCFA was adjusted to offer quantities similar to those ingested orally. Saline solutions had the same pH and osmolarity of corresponding solutions. Experimental protocols (Ara-C administration, histopathology, and morphometry) were done as described previously (11) .
The oral intake of SCFA and saline was 4.47 Ϯ 0.23 and 4.35 Ϯ 0.15 ml/day/mouse, respectively, and the volume administered intragastrically was 0.3 ml/day/mouse.
Since the histology was very similar in all control groups (Normal, SCFA/OϩSal, and SCFA/IGϩSal) the histopathology of the Sal/OϩSal group was used as the representative of the controls (Fig. 1A) . Similarly, the Sal/OϩAra-C group (given saline orally and 3.6 mg of Ara-C per day per mouse intraperitoneally) was used to illustrate the lesions present in both Sal/OϩAra-C and Sal/IGϩAra-C groups, since no difference was seen between the treatments (Fig. 1B) .
Ara-C administration induced severe intestinal lesions (shortening of villi, reduction in the number of enterocytes, inflammatory infiltration, and necrosis; Fig. 1B ). SCFA administration improved the mucosa integrity, avoiding necrosis and increasing villus length, compared to the SalϩAra-C groups (Fig. 1B to D) . Morphological analysis showed that both total mucosa length and villus length were statistically lower in SalϩAra-C groups than in SCFA and the three control groups (Fig. 2) . However, the SCFAϩAra-C groups still had reductions in villus length compared to control groups.
Regarding the administration route, histopathological alterations were less intensive and morphology was closer to normal in SCFA/OϩAra-C mice than in SCFA/IGϩAra-C animals ( Fig. 1C and D) . Shortened and fused villi were still observed in SCFA/IGϩAra-C animals, suggesting a worse villus pattern when SCFA were given as a single dose. Microvascular fat accumulation was seen only in hepatocytes from SCFA/IG animals (Fig. 3) .
Colon lesions were less intensive than those in the small intestines of orally or intragastrically treated groups. This finding could be due to the lower turnover of colonocytes than that of enterocytes. The administration route (oral or intragastric) did not influence colonic histology (data not shown).
SCFAϩAra-C animals had a greater colon length than mice in the SalϩAra-C group (data not shown). No differences were seen between SCFAϩSal and SCFAϩAra-C groups. Colonic morphometry was similar between oral and intragastric treatments.
The results show that the same quantity of SCFA used in conventionally reared mice offered similar protection against Ara-C damage in germfree animals when both intragastric or oral solutions were administered, suggesting that the protec- tive effect of SCFA was independent of endogenous production.
In the present study, hepatic fat accumulation was related to the intragastric administration of SCFA. In our previous studies using conventionally reared animals, intestinal and hepatic fat accumulation was seen only when high doses were administered (11) . It is known that SCFA are rapidly metabolized by the gastrointestinal tract. The SCFA not metabolized by the mucosal epithelium are transported to the liver and can be incorporated into longer-chain fatty acid and/or may originate ketone bodies (4, 12) . Propionate can be used as a substrate for gluconeogenesis (1) . Probably, the high concentrations of SCFA (as those given intragastrically) induced a higher captation of SCFA by the intestinal tract and liver and their metabolization to fatty acids or other lipids with the consequent lipid accumulation.
Independently of the presence of fat accumulation, SCFA administered both orally and intragastrically were able to improve intestinal mucosa integrity when compared to the results for the SalϩAra-C groups. Although animals in the SCFA/ OϩSal group had a moderately better morphology of intestinal mucosa than those receiving SCFA intragastrically, the villus length of animals receiving SCFA intragastrically and Ara-C was about five times greater than that of mice in the SalϩAra-C group and similar to that of mice in the SCFA/ OϩAra-C groups, confirming the advantages of the administration of SCFA during chemotherapy, even as a single dose. It is now clear that the trophic effect of SCFA is due not only to the simple provision of energy to the host but also to the combination of local action and systemic metabolism of SCFA (2, 3, 6, 7) . The result of all these SCFA actions is a faster recovery of intestinal and colonic mucosa damaged by Ara-C treatment. We have demonstrated that this protection can be obtained by oral doses of SCFA.
These results indicate a new potential clinical use for SCFA. Chemotherapy for leukemia and other neoplasias leads to mucosal atrophy, diarrhea and malnutrition caused by alterations in absorption, and sometimes death. Besides trophic effects, SCFA administration has been described as useful in the prevention or treatment in vivo and in vitro of several diseases (5) and cancers (14) , especially colon cancer (8, 9) , inducing cell cycle arrest and apoptosis or interfering with the expression of oncogenes. However, a clinical trial in humans is needed to determine if a similar reduction in drug toxicity would be obtained.
